This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Opioid Analgesics Market

Hospital Pharmacies to be the Key Revenue Channel for Opioid Analgesics Market. Get Key Facts with FMI

Opioid Analgesics Market By Drug Class, Indication, Route of Administration, End User, Region - Forecast 2022-2032

Opioid Analgesics Market Outlook (2022-2032)

[306 Pages Report] According to a recent assessment by Future Market Insights (FMI), the opioid analgesics market is slated to expand at a 5.4% CAGR, attaining a worth of US$ 41.11 Billion in 2022. Soaring demand for post-surgery pain management and advancements in drug formulations to reduce analgesic side effects are predicted to propel sales of opioid analgesics over the forecast period.

Morphin sales are expected to command 13% of the overall opioid analgesics market share, with a market valuation of US$ 69.55 billion in 2032, according to FMI.

Attributes

Details

Opioid Analgesics Market CAGR (2022-2032)

5.4%

Opioid Analgesics Market Size (2022)

US$ 41.11 Billion

Opioid Analgesics Market Size (2030)

US$ 62.61 Billion

Opioid Analgesics Market Size (2032)

US$ 69.55 billion

Customize this Report

Let us know your requirement to get
100% FREE customization

The Opioid Analgesics Key Determinants - Creating Hype

Opioid analgesics are widely ideal drugs for pain management and palliative care due to their convenience and efficacy. However, in order to reduce the risk of addiction and overuse, definite restrictions on opioid sales are in place.

As a result, manufacturers are trying to enhance their product offerings by investing in research and development to develop milder and less addictive drugs. This points to lucrative opioid analgesics market growth opportunities for key opioid analgesics manufacturers.

The Valuable Opportunities for Market Makers in the Couple of years

On the other hand, many people believe that smaller doses of opioids are ineffective in alleviating severe pain. These patients require a higher dose of drugs to relieve their pain, which leads inevitably to opioid tolerance and, in some cases, addiction to these drugs.

One of the primary opportunities for opioid analgesics market manufacturers in the opioid drugs market is expected to be the commercialization of opioid-tolerant drugs. This will help to reduce the side effects caused by or associated with high opioid drug consumption, which will boost sales of opioid analgesics in the coming years.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

The Opioid Analgesics Market's Hurdles

Will the rising prevalence of opioid addiction harm sales?

The primary factors limiting the opioid analgesics market growth are the unavailability of opioids in emerging markets and the side effects associated with these drugs. Aside from that, the escalating magnitude of abusive opioids and their misuse is a major impediment to opioid analgesics market growth.

Furthermore, chronic opioid side effects pose a significant barrier to the market growth. Due to the increased abuse of addictive opioids, physicians have scaled back their prescription for pain management, resulting in a decrease in global sales. The rising prevalence of opioid abuse is expected to stifle opioid analgesics market growth, as practitioners are hesitant to prescribe opioids as a pain reliever.

Comparative View of Adjacent Opioid Analgesics Market

Opioid Analgesics Market:

Attributes

Opioid Analgesics Market

CAGR (2022-2032)

5.4%

Market Value (2027)

US$ 53.47 Billion

Growth Factor

A significant driver for the market is the rising prevalence of orthopaedic diseases, cancer, and chronic pain among the geriatric population.

Opportunity

The Opioid Analgesics Market is being fueled by rising healthcare costs and rising disposable income.

Key Trends

It is anticipated that the primary opportunities for manufacturers in the opioid drug market will be the commercialization of opioid-tolerant drugs.

Pain Management Drugs Market:

Attributes

Pain Management Drugs Market

CAGR (2022-2032)

3.8%

Market Value (2027)

US $91,649.16 million

Growth Factor

The growing geriatric population is a major driver of the global pain management drugs market, as older people are more likely to suffer from joint pain and other chronic conditions.

Opportunity

The increase in the number of surgical procedures and the increase in healthcare spending are expected to drive the growth of the pain management drugs market.

Key Trends

The rising prevalence of chronic diseases such as cancer, diabetic neuropathy, and osteoarthritis drives market expansion.

Opioid Use Disorder Market:

Attributes

Opioid Use Disorder Market

CAGR (2022-2032)

11.5%

Market Value (2027)

US$ 5.38 Billion

Growth Factor

The increase in the prevalence of chronic diseases is expected to drive the growth of the global opioid use disorder market.

Opportunity

The increase in product launch and approval for opioid use disorder drugs is expected to fuel the growth of the opioid use disorder market.

Key Trends

The anticipated rise in the prevalence of chronic diseases fuels the demand for opioid use disorder drugs, boosting market growth.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Which is the Leading Segment in the Opioid Analgesics Market by Drug Class?

According to the drug class, oxycodone is expected to account for 19.4% of the opioid analgesics market. Oxycodone is one of the most potent pain relievers on the market. The medication effectively relieves pain and allows patients to go about their daily activities.

Previously, oxycodone was not widely used due to a lack of knowledge about the constituents and the high cost of drugs. The rising awareness about the benefits of oxycodone, such as increased bioavailability, is encouraging the drug's use.

Which is the Leading Segment in the Opioid Analgesics Market by Indication?

Due to the rising number of surgical procedures and the increasing incidence of associated post-operative pain, the surgical pain indication is expected to account for 45.9% of the opioid analgesics market share.

Opioid analgesics are used as an effective treatment for pain management following an operation or surgery. Over the forecast period, increased adoption of medications for pain management and relief is expected to drive demand for opioid analgesics.

Which is the Leading Segment in the Opioid Analgesics Market by Route of Administration?

The hospital pharmacies are expected to account for 33.1% of the total opioid analgesics market share. Hospitals are major care facilities with a large presence of well-trained staff and professionals who assist patients in receiving effective treatment. Adoption of prescribed therapy in clinics and hospitals aids in physician-supervised drug delivery. This is one of the primary factors driving sales of opioid analgesics through hospital pharmacies.

Regions of High Interest in the Opioid Analgesics Market

What Renders the United States an Enticing Opioid Analgesics Market?

The United States is expected to dominate the North American opioid analgesics market, accounting for 86% of the opioid analgesics market. The rising prevalence of chronic illnesses, as well as the growing adoption of opioid analgesics as a pain reliever, is expected to continue to boost sales of opioid analgesics.

Key opioid analgesic manufacturers in the United States are focusing on launching new products to comply with updated regulatory procedures. Furthermore, government-led investments in clinical research will enable the country to maintain its dominance over the forecast period.

What is the Demand Perspective for Opioid Analgesics in Germany?

In Germany, sales of opioid analgesics are expected to grow at a 3.8% CAGR, reaching a valuation of US$ 2.2 billion in 2021.

Adoption of opioid maintenance treatment (OMT) for the treatment of opioid dependence (OD), increased use of non-abusive opioids, and favourable reimbursement programmes offered by German regulatory bodies regarding awareness of palliative care are key factors driving sales of opioid analgesics in Germany.

Maddening Buzz about Opioid Analgesics Recorded in United Kingdom

The United Kingdom is expected to lead the European opioid analgesics market, with sales increasing at a 4.7% CAGR during the forecast period.

The healthcare system in the United Kingdom is well-known and universal, with significant government funding. It is widely regarded as having one of the most thriving and successful healthcare systems in the world.

The United Kingdom is the third-largest opioid analgesics market, and this position is expected to be maintained throughout the forecast period. Furthermore, the presence of several major players, expanding pipeline drugs, and increasing research efforts create lucrative opioid analgesics market opportunities in the United Kingdom.

Why is China perceived as an emerging country for opioid analgesics?

China is expected to lead the East Asian market in 2021, accounting for 54.2% of the opioid analgesics market share. Due to increasing use of large amounts of opioids for pain management and its extensive manufacturing capacity, China dominates the East Asian market.

Due to rapid productivity and large-scale capital investments in the healthcare sector, China is the world's second-largest pharmaceutical market.

How will India's sales of opioid analgesics fare?

India is anticipated to account for 35.4% of the South Asian market for opioid analgesics, with sales increasing at a steady 5.7% CAGR.

Due to the nation's rising need for opioid analgesics, both small and large pharmaceutical companies in India are actively funding research and development. Many innovative drugs in the funnel are mostly finished and will be made accessible to patients soon.

Clinical trials for opioid analgesics are made possible by the existence of government-funded healthcare and pharmaceutical institutions in India. In the upcoming years, it is anticipated that the increase in research activities underway in India will fuel the opioid analgesics market growth.

What is the State of the Start-up Ecosystem in the Opioid Analgesics Market?

  • Novaremed

With the addition of two complementary development initiatives, the acquisition of Metys expands Novaremed's pipeline of novel, non-opioid development candidates for chronic pain indications.

With the addition of chemotherapy-induced peripheral neuropathy (CIPN) to its current focus on excruciating diabetic peripheral neuropathy, Novaremed's pipeline expansion enables it to target a wider segment of neuropathic pain indications (PDPN).

  • Pharmachal

Turning Point Therapeutics, Inc. was successfully acquired by Bristol Myers Squibb in an all-cash deal, the company announced. Turning Point is now a fully owned subsidiary of Bristol Myers Squibb after the acquisition was finalised, and shares of Turning Point no longer trade on the NASDAQ Global Select Market.

  • AntalGenics

AntalGenics, a Spanish start-up, created novel molecules to treat chronic pain. The start-up is currently looking into two molecules, AG1529 and AG1531, to treat osteoarthritis pain and psoriatic pruritus. Additionally, the startup creates cosmetic active ingredients for skin and scalp sensitivity.

At in-cosmetics Virtual 2020, AntalGenics will introduce two of its cutting-edge neurocosmetic ingredients: Capsisilence, which promotes a healthy scalp, and Calmapsin, which lessens the signs of sensitive skin.

  • InnoPain

A drug to mimic the effects of morphine without the negative side effects is being developed by the French startup InnoPain. The analgesic effect of morphine is produced by an interaction between the startup's lead candidate, TREK-1, and the -opioid receptor (OR). The startup is also working on RNE28, a brand-new class of oral and intravenous analgesic medications.

  • Neumentum

The pharmaceutical company Neumentum has raised $6 million in a Series A funding round by selling Series A Convertible Preferred Stock. Neumentum is committed to revolutionising the way acute and chronic pain is treated without the use of opioids. The sole placement agent for the financing was Brookline Capital Markets.

How Does Intensity of Rivalry Affect the Opioid Analgesics Market?

Crucial players are trying to emphasize product portfolio expansion by launching new and updated products in emerging opioid analgesics market. Players in the market for opioid analgesics are anticipated to benefit from product approvals, agreements, partnerships, facility expansion, and strategic collaborations to achieve a competitive advantage.

Pfizer Inc, Abbott Laboratories, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Bayer AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., and Sanofi S.A. are some of the significant players operating in market for opioid analgesics.

Recent Development

Date May 2020
Company Assertio Therapeutics, Inc.
Strategy Merger
Details Assertio Therapeutics, Inc. will merge with Zyla Life Sciences. The merger enabled the companies to broaden their product portfolios in neurology, inflammation, and chronic pain.
Date September 2021
Company Bausch Health Companies Inc.
Strategy Data
Details Bausch Health Companies Inc. and its gastroenterology business, Salix, will present RELISTOR® (Methylnaltrexone Bromide) data at PAINWeek 2021. The opioid antagonist RELISTOR® (methylnaltrexone bromide) RELISTOR tablets and RELISTOR injection are approved to treat opioid-induced constipation (OIC) in adults suffering from chronic non-cancer pain.
Date August 08, 2022
Company Global Blood Therapeutics, Inc. (GBT)
Strategy Agreement
Details Global Blood Therapeutics, Inc. (GBT), and Pfizer Inc., announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT (SCD).
Date August 23, 2022
Company F. Hoffmann-La Roche AG
Strategy Introduction
Details In the fight against cancer and other diseases, Roche introduces a powerful new diagnostics platform called the digital PCR system.
Date January 2020
Company Allergan PLC
Strategy Product Launch
Details The new drug application that Allergan PLC submitted in January 2020 has been approved by the FDA. The application was made by a business called DURYSTA for the Food and Drug Administration. It is the first of its kind and aims to lower intraocular pressure by giving sustained-release, biodegradable medication. Due to open-angle glaucoma and ocular hypertension (OHT), this is possible.
Date December 1st, 2019
Company Veritas Pharma Inc
Strategy Collaboration
Details The FDA disclosed that the Prescription Drug User Fee Act (PDUFA) would go into effect on December 1st, 2019, at Veritas Pharma Inc. In 2020, Daiichi Sankyo declared that it would collaborate with Ultragenyx Pharmaceutical to enhance research.

Key Players

  • Pfizer Inc.
  • Abbott Laboratories
  • Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG,
  • Boehringer Ingelheim International GmbH
  • Bausch Health Companies Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals
  • AbbVie Inc. (Allergan plc)
  • Purdue Pharmaceuticals L.P.
  • Sun Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc. [Endo International plc]
  • Assertio Therapeutics, Inc. [Assertio Holdings, Inc.]

Key Segments

By Drug Class:

  • Morphine
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Tramadol
  • Oxycodone
  • Dextromethorphan
  • Buprenorphine
  • Others

By Indication:

  • Surgical Pain
  • Cancer Pain
  • Neuropathic Pain
  • Other

By Route of Administration:

  • Oral
  • Parenteral
  • Transdermal
  • Other

By End User:

  • Hospitals
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

The opioid analgesics market is predicted to grow at 5.4% CAGR through 2032.

Asia Pacific opioid analgesics market holds the highest revenue potential.

The opioid analgesics market size is anticipated to be over US$ 41.11 Billion in 2022.

The market for opioid analgesics is expected to surpass US$ 69.55 billion by 2032.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Market Context

    4.1. Drug Adoption / Usage Analysis

    4.2. Key Strategies Adopted By Manufactures

    4.3. Regulatory Scenario

5. Key Inclusion

    5.1. Drug Adoption / Usage Analysis

    5.2. Key Strategies Adopted By Manufactures

    5.3. Regulatory Scenario

6. Market Background

    6.1. Macro-Economic Factors

        6.1.1. Global GDP Growth Outlook

        6.1.2. Global Healthcare Outlook

    6.2. Forecast Factors - Relevance & Impact

        6.2.1. Increasing Prevalence of Chronic Disease and Surgical Procedures

        6.2.2. Increasing Prevalence of Neuropathic and Chronic pain

        6.2.3. Elevating Awareness about Palliative Care and Pain Management

    6.3. Market Dynamics

        6.3.1. Drivers

        6.3.2. Restraints

        6.3.3. Opportunity Analysis

    6.4. Value Chain Analysis

7. COVID19 Crisis Analysis

        7.1.1. Current COVID19 Statistics and Probable Future Impact

        7.1.2. Current GDP Projection and Probable Impact

        7.1.3. Current Economic Projection as compared to 2008 Economic analysis

        7.1.4. COVID19 and Impact Analysis

            7.1.4.1. Revenue By Product

            7.1.4.2. Revenue By Country

8. Global Analgesics Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022–2032

    8.1. Historical Market Value (US$ Mn) Analysis, 2017-2021

    8.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        8.2.1. Y-o-Y Growth Trend Analysis

        8.2.2. Absolute $ Opportunity Analysis

9. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, By Drug Class

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2017-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022–2032

        9.3.1. Morphine

        9.3.2. Codeine

        9.3.3. Fentanyl

        9.3.4. Meperidine

        9.3.5. Methadone

        9.3.6. Tramadol

        9.3.7. Oxycodone

        9.3.8. Dextromethorphan

        9.3.9. Buprenorphine

        9.3.10. Others

10. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, by Indication

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2017-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast Indication, 2022 – 2032

        10.3.1. Surgical Pain

        10.3.2. Cancer Pain

        10.3.3. Neuropathic Pain

        10.3.4. Other

    10.4. Market Attractiveness Analysis By Indications

11. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, by Route of Administration

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2017-2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast Route of Administration, 2022–2032

        11.3.1. Oral

        11.3.2. Parenteral

        11.3.3. Transdermal

        11.3.4. Others

    11.4. Market Attractiveness Analysis By Route of Administration

12. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, by Distribution Channel

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017-2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022–2032

        12.3.1. Hospitals

        12.3.2. Retail Pharmacies

        12.3.3. Drug Stores

        12.3.4. Online Pharmacies

    12.4. Market Attractiveness Analysis By Distribution Channel

13. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, by Region

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021

    13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032

        13.3.1. North America

        13.3.2. Latin America

        13.3.3. Europe

        13.3.4. South Asia

        13.3.5. East Asia

        13.3.6. Oceania

        13.3.7. Middle East & Africa

    13.4. Market Attractiveness Analysis By Region

14. North America Analgesics Market Analysis 2017-2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        14.3.1. By Drug Class

        14.3.2. By Indication

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

        14.3.5. By Country

            14.3.5.1. U.S.

            14.3.5.2. Canada

    14.4. Market Attractiveness Analysis

    14.5. Drivers and Restraints-Impact Analysis

15. Latin America Analgesics Market Analysis 2017-2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        15.3.1. By Drug Class

        15.3.2. By Indication

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

        15.3.5. By Country

            15.3.5.1. Brazil

            15.3.5.2. Mexico

            15.3.5.3. Argentina

            15.3.5.4. Rest of Latin America

    15.4. Market Attractiveness Analysis

    15.5. Drivers and Restraints-Impact Analysis

16. Europe Analgesics Market Analysis 2017-2021 and Forecast 2022–2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        16.3.1. By Drug Class

        16.3.2. By Indication

        16.3.3. By Route of Administration

        16.3.4. By Distribution Channel

        16.3.5. By Country

            16.3.5.1. Germany

            16.3.5.2. Italy

            16.3.5.3. France

            16.3.5.4. U.K.

            16.3.5.5. Spain

            16.3.5.6. BENELUX

            16.3.5.7. Russia

            16.3.5.8. Rest of Europe

    16.4. Market Attractiveness Analysis

    16.5. Drivers and Restraints-Impact Analysis

17. South Asia Analgesics Market Analysis 2017-2021 and Forecast 2022–2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        17.3.1. By Drug Class

        17.3.2. By Indication

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

        17.3.5. By Country

            17.3.5.1. India

            17.3.5.2. Thailand

            17.3.5.3. Indonesia

            17.3.5.4. Malaysia

            17.3.5.5. Rest of South Asia

    17.4. Market Attractiveness Analysis

    17.5. Drivers and Restraints-Impact Analysis

18. East Asia Analgesics Market Analysis 2017-2021 and Forecast 2022–2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        18.3.1. By Drug Class

        18.3.2. By Indication

        18.3.3. By Route of Administration

        18.3.4. By Distribution Channel

        18.3.5. By Country

            18.3.5.1. China

            18.3.5.2. Japan

            18.3.5.3. South Korea

    18.4. Market Attractiveness Analysis

    18.5. Drivers and Restraints-Impact Analysis

19. Oceania Analgesics Market Analysis 2017-2021 and Forecast 2022–2032

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        19.3.1. By Drug Class

        19.3.2. By Indication

        19.3.3. By Route of Administration

        19.3.4. By Distribution Channel

        19.3.5. By Country

            19.3.5.1. Australia

            19.3.5.2. New Zealand

    19.4. Market Attractiveness Analysis

    19.5. Drivers and Restraints-Impact Analysis

20. Middle East and Africa Analgesics Market Analysis 2017-2021 and Forecast 2022–2032

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

        20.3.1. By Drug Class

        20.3.2. By Indication

        20.3.3. By Route of Administration

        20.3.4. By Distribution Channel

        20.3.5. By Country

            20.3.5.1. GCC Countries

            20.3.5.2. Turkey

            20.3.5.3. Northern Africa

            20.3.5.4. South Africa

            20.3.5.5. Rest of Middle East and Africa

    20.4. Market Attractiveness Analysis

    20.5. Drivers and Restraints-Impact Analysis

21. Key and Emerging Countries Analgesics Market Analysis

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, By Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. U.S. Analgesics Market Analysis

        21.2.1. By Drug Class

        21.2.2. By Indication

        21.2.3. By Route of Administration

        21.2.4. By Distribution Channel

    21.3. Canada Analgesics Market Analysis

        21.3.1. By Drug Class

        21.3.2. By Indication

        21.3.3. By Route of Administration

        21.3.4. By Distribution Channel

    21.4. Mexico Analgesics Market Analysis

        21.4.1. By Drug Class

        21.4.2. By Indication

        21.4.3. By Route of Administration

        21.4.4. By Distribution Channel

    21.5. Brazil Analgesics Market Analysis

        21.5.1. By Drug Class

        21.5.2. By Indication

        21.5.3. By Route of Administration

        21.5.4. By Distribution Channel

    21.6. Germany Analgesics Market Analysis

        21.6.1. By Drug Class

        21.6.2. By Indication

        21.6.3. By Route of Administration

        21.6.4. By Distribution Channel

    21.7. Italy Analgesics Market Analysis

        21.7.1. By Drug Class

        21.7.2. By Indication

        21.7.3. By Route of Administration

        21.7.4. By Distribution Channel

    21.8. France Analgesics Market Analysis

        21.8.1. By Drug Class

        21.8.2. By Indication

        21.8.3. By Route of Administration

        21.8.4. By Distribution Channel

    21.9. U.K. Analgesics Market Analysis

        21.9.1. By Drug Class

        21.9.2. By Indication

        21.9.3. By Route of Administration

        21.9.4. By Distribution Channel

    21.10. Spain Analgesics Market Analysis

        21.10.1. By Drug Class

        21.10.2. By Indication

        21.10.3. By Route of Administration

        21.10.4. By Distribution Channel

    21.11. BENELUX Analgesics Market Analysis

        21.11.1. By Drug Class

        21.11.2. By Indication

        21.11.3. By Route of Administration

        21.11.4. By Distribution Channel

    21.12. Russia Analgesics Market Analysis

        21.12.1. By Drug Class

        21.12.2. By Indication

        21.12.3. By Route of Administration

        21.12.4. By Distribution Channel

    21.13. China Analgesics Market Analysis

        21.13.1. By Drug Class

        21.13.2. By Indication

        21.13.3. By Route of Administration

        21.13.4. By Distribution Channel

    21.14. Japan Analgesics Market Analysis

        21.14.1. By Drug Class

        21.14.2. By Indication

        21.14.3. By Route of Administration

        21.14.4. By Distribution Channel

    21.15. South Korea Analgesics Market Analysis

        21.15.1. By Drug Class

        21.15.2. By Indication

        21.15.3. By Route of Administration

        21.15.4. By Distribution Channel

    21.16. India Analgesics Market Analysis

        21.16.1. By Drug Class

        21.16.2. By Indication

        21.16.3. By Route of Administration

        21.16.4. By Distribution Channel

    21.17. ASEAN Analgesics Market Analysis

        21.17.1. By Drug Class

        21.17.2. By Indication

        21.17.3. By Route of Administration

        21.17.4. By Distribution Channel

    21.18. Australia Analgesics Market Analysis

        21.18.1. By Drug Class

        21.18.2. By Indication

        21.18.3. By Route of Administration

        21.18.4. By Distribution Channel

    21.19. New Zealand Analgesics Market Analysis

        21.19.1. By Drug Class

        21.19.2. By Indication

        21.19.3. By Route of Administration

        21.19.4. By Distribution Channel

    21.20. GCC Countries Analgesics Market Analysis

        21.20.1. By Drug Class

        21.20.2. By Indication

        21.20.3. By Route of Administration

        21.20.4. By Distribution Channel

    21.21. Turkey Analgesics Market Analysis

        21.21.1. By Drug Class

        21.21.2. By Indication

        21.21.3. By Route of Administration

        21.21.4. By Distribution Channel

    21.22. South Africa Analgesics Market Analysis

        21.22.1. By Drug Class

        21.22.2. By Indication

        21.22.3. By Route of Administration

        21.22.4. By Distribution Channel

22. Market Structure Analysis

    22.1. Market Share Analysis

    22.2. Market Analysis by Tier of Companies

    22.3. Market Concentration

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Deep Dive

        23.2.1. Pfizer Inc.

            23.2.1.1. Overview

            23.2.1.2. Product Offering

            23.2.1.3. Regional Footprint

            23.2.1.4. Strategy Overview

                23.2.1.4.1. Marketing Strategy

                23.2.1.4.2. Product Strategy

                23.2.1.4.3. Channel Strategy

        23.2.2. Sun Pharmaceutical Industries, Inc.

            23.2.2.1. Overview

            23.2.2.2. Product Offering

            23.2.2.3. Regional Footprint

            23.2.2.4. Strategy Overview

                23.2.2.4.1. Marketing Strategy

                23.2.2.4.2. Product Strategy

                23.2.2.4.3. Channel Strategy

        23.2.3. Sanofi SA

            23.2.3.1. Overview

            23.2.3.2. Product Offering

            23.2.3.3. Regional Footprint

            23.2.3.4. Strategy Overview

                23.2.3.4.1. Marketing Strategy

                23.2.3.4.2. Product Strategy

                23.2.3.4.3. Channel Strategy

        23.2.4. AbbVie Inc. (Allergan plc)

            23.2.4.1. Overview

            23.2.4.2. Product Offering

            23.2.4.3. Regional Footprint

            23.2.4.4. Strategy Overview

                23.2.4.4.1. Marketing Strategy

                23.2.4.4.2. Product Strategy

                23.2.4.4.3. Channel Strategy

        23.2.5. Teva Pharmaceuticals

            23.2.5.1. Overview

            23.2.5.2. Product Offering

            23.2.5.3. Regional Footprint

            23.2.5.4. Strategy Overview

                23.2.5.4.1. Marketing Strategy

                23.2.5.4.2. Product Strategy

                23.2.5.4.3. Channel Strategy

        23.2.6. Boehringer Ingelheim International GmbH

            23.2.6.1. Overview

            23.2.6.2. Product Offering

            23.2.6.3. Regional Footprint

            23.2.6.4. Strategy Overview

                23.2.6.4.1. Marketing Strategy

                23.2.6.4.2. Product Strategy

                23.2.6.4.3. Channel Strategy

        23.2.7. Janssen Pharmaceuticals, Inc. [Johnson & Johnson]

            23.2.7.1. Overview

            23.2.7.2. Product Offering

            23.2.7.3. Regional Footprint

            23.2.7.4. Strategy Overview

                23.2.7.4.1. Marketing Strategy

                23.2.7.4.2. Product Strategy

                23.2.7.4.3. Channel Strategy

        23.2.8. Endo Pharmaceuticals Inc.

            23.2.8.1. Overview

            23.2.8.2. Product Offering

            23.2.8.3. Regional Footprint

            23.2.8.4. Strategy Overview

                23.2.8.4.1. Marketing Strategy

                23.2.8.4.2. Product Strategy

                23.2.8.4.3. Channel Strategy

        23.2.9. Purdue Pharmaceuticals L.P.

            23.2.9.1. Overview

            23.2.9.2. Product Offering

            23.2.9.3. Regional Footprint

            23.2.9.4. Strategy Overview

                23.2.9.4.1. Marketing Strategy

                23.2.9.4.2. Product Strategy

                23.2.9.4.3. Channel Strategy

        23.2.10. Assertio Therapeutics, Inc.

            23.2.10.1. Overview

            23.2.10.2. Product Offering

            23.2.10.3. Regional Footprint

            23.2.10.4. Strategy Overview

                23.2.10.4.1. Marketing Strategy

                23.2.10.4.2. Product Strategy

                23.2.10.4.3. Channel Strategy

        23.2.11. Mallinckrodt Pharmaceuticals

            23.2.11.1. Overview

            23.2.11.2. Product Offering

            23.2.11.3. Regional Footprint

            23.2.11.4. Strategy Overview

                23.2.11.4.1. Marketing Strategy

                23.2.11.4.2. Product Strategy

                23.2.11.4.3. Channel Strategy

        23.2.12. Bayer AG

            23.2.12.1. Overview

            23.2.12.2. Product Offering

            23.2.12.3. Regional Footprint

            23.2.12.4. Strategy Overview

                23.2.12.4.1. Marketing Strategy

                23.2.12.4.2. Product Strategy

                23.2.12.4.3. Channel Strategy

        23.2.13. GlaxoSmithKline plc.

            23.2.13.1. Overview

            23.2.13.2. Product Offering

            23.2.13.3. Regional Footprint

            23.2.13.4. Strategy Overview

                23.2.13.4.1. Marketing Strategy

                23.2.13.4.2. Product Strategy

                23.2.13.4.3. Channel Strategy

        23.2.14. Bausch Health Companies Inc.

            23.2.14.1. Overview

            23.2.14.2. Product Offering

            23.2.14.3. Regional Footprint

            23.2.14.4. Strategy Overview

                23.2.14.4.1. Marketing Strategy

                23.2.14.4.2. Product Strategy

                23.2.14.4.3. Channel Strategy

        23.2.15. Novartis AG

            23.2.15.1. Overview

            23.2.15.2. Product Offering

            23.2.15.3. Regional Footprint

            23.2.15.4. Strategy Overview

                23.2.15.4.1. Marketing Strategy

                23.2.15.4.2. Product Strategy

                23.2.15.4.3. Channel Strategy

        23.2.16. Others

            23.2.16.1. Overview

            23.2.16.2. Product Offering

            23.2.16.3. Regional Footprint

            23.2.16.4. Strategy Overview

                23.2.16.4.1. Marketing Strategy

                23.2.16.4.2. Product Strategy

                23.2.16.4.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Expenditure on Health, (% of GDP), by Country, 2017 - 2022

Table 02: Expenditure on Health, (% of GDP), by Country, 2017 - 2022

Table 03: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Table 04: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Table 05: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Table 06: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Table 07: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Region

Table 08: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 09: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Table 10: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Table 11: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Table 12: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Table 13: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 14: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Table 15: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Table 16: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Table 17: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Table 18: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 19: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Table 20: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Table 21: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Table 22: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Table 23: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 24: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Table 25: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Table 26: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Table 27: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Table 28: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 29: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Table 30: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Table 31: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Table 32: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Table 33: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 34: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Table 35: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Table 36: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Table 37: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Table 38: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country

Table 39: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Table 40: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Table 41: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Table 42: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01 : Global Opioid Analgesics Market Value (US$ Mn) Forecast, 2022 – 2032

Figure 02 : Global Opioid Analgesics Market Share, By Drug Class (2022)

Figure 03 : Global Opioid Analgesics Market Share, By Region (2022)

Figure 04: Global Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021

Figure 05: Global Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 06: Global Opioid Analgesics Market Absolute $ Opportunity Analysis, 2022-2032

Figure 07: Global Opioid Analgesics Market Analysis By Drug Class–2022 & 2032

Figure 08: Global Opioid Analgesics Market Y-o-Y Growth Projections By Drug Class, 2022-2032

Figure 09: Global Opioid Analgesics Market Attractiveness, By Drug Class

Figure 10: Global Opioid Analgesics Market Analysis By Indication–2022 & 2032

Figure 11: Global Opioid Analgesics Market Y-o-Y Growth Projections By Indication, 2022-2032

Figure 12: Global Opioid Analgesics Market Attractiveness, By Indication

Figure 13: Global Opioid Analgesics Market Analysis By Route of Administration – 2022 & 2032

Figure 14: Global Opioid Analgesics Market Y-o-Y Growth Projections By Route of Administration, 2022-2032

Figure 15: Global Opioid Analgesics Market Attractiveness, By Route of Administration

Figure 16: Global Opioid Analgesics Market Analysis By Distribution Channel–2022 & 2032

Figure 17: Global Opioid Analgesics Market Y-o-Y Growth Projections By Distribution Channel, 2022-2032

Figure 18: Global Opioid Analgesics Market Attractiveness, By Distribution Channel

Figure 19: Global Opioid Analgesics Market Analysis by Region–2022 & 2032

Figure 20: Global Opioid Analgesics Market Y-o-Y Growth Projections by Region, 2022-2032

Figure 21: Global Opioid Analgesics Market Attractiveness, By Region

Figure 22: North America Opioid Analgesics Market Share, By Drug Class, 2022 (E)

Figure 23: North America Opioid Analgesics Market Share, By Indication, 2022 (E)

Figure 24: North America Opioid Analgesics Market Share, By Route of Administration, 2022 (E)

Figure 25: North America Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)

Figure 26: North America Opioid Analgesics Market Share, By Country, 2022 (E)

Figure 27: North America Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021

Figure 28: North America Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 29: North America Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country

Figure 30: North America Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class

Figure 31: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Figure 32: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Figure 33: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Figure 34: Latin America Opioid Analgesics Market Share, By Drug Class, 2022 (E)

Figure 35: Latin America Opioid Analgesics Market Share, By Indication, 2022 (E)

Figure 36: Latin America Opioid Analgesics Market Share, By Route of Administration, 2022 (E)

Figure 37: Latin America Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)

Figure 38: Latin America Opioid Analgesics Market Share, By Country, 2022 (E)

Figure 39: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021

Figure 40: Latin America Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 41: Latin America Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country

Figure 42: Latin America Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class

Figure 43: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Figure 44: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Figure 45: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Figure 46: Europe Opioid Analgesics Market Share, By Drug Class, 2022 (E)

Figure 47: Europe Opioid Analgesics Market Share, By Indication, 2022 (E)

Figure 48: Europe Opioid Analgesics Market Share, By Route of Administration, 2022 (E)

Figure 49: Europe Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)

Figure 50: Europe Opioid Analgesics Market Share, By Country, 2022 (E)

Figure 51: Europe Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021

Figure 52: Europe Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 53: Europe Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country

Figure 54: Europe Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class

Figure 55: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Figure 56: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Figure 57: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Figure 58: South Asia Opioid Analgesics Market Share, By Drug Class, 2022 (E)

Figure 59: South Asia Opioid Analgesics Market Share, By Indication, 2022 (E)

Figure 60: South Asia Opioid Analgesics Market Share, By Route of Administration, 2022 (E)

Figure 61: South Asia Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)

Figure 62: South Asia Opioid Analgesics Market Share, By Country, 2022 (E)

Figure 63: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021

Figure 64: South Asia Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 65: South Asia Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country

Figure 66: South Asia Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class

Figure 67: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Figure 68: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Figure 69: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Figure 70: East Asia Opioid Analgesics Market Share, By Drug Class, 2022 (E)

Figure 71: East Asia Opioid Analgesics Market Share, By Indication, 2022 (E)

Figure 72: East Asia Opioid Analgesics Market Share, By Route of Administration, 2022 (E)

Figure 73: East Asia Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)

Figure 74: East Asia Opioid Analgesics Market Share, By Country, 2022 (E)

Figure 75: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021

Figure 76: East Asia Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 77: East Asia Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country

Figure 78: East Asia Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class

Figure 79: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Figure 80: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Figure 81: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Figure 82: Oceania Opioid Analgesics Market Share, By Drug Class, 2022 (E)

Figure 83: Oceania Opioid Analgesics Market Share, By Indication, 2022 (E)

Figure 84: Oceania Opioid Analgesics Market Share, By Route of Administration, 2022 (E)

Figure 85: Oceania Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)

Figure 86: Oceania Opioid Analgesics Market Share, By Country, 2022 (E)

Figure 87: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021

Figure 88: Oceania Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 89: Oceania Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country

Figure 90: Oceania Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class

Figure 91: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Figure 92: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Figure 93: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Figure 94: MEA Opioid Analgesics Market Share, By Drug Class, 2022 (E)

Figure 95: MEA Opioid Analgesics Market Share, By Indication, 2022 (E)

Figure 96: MEA Opioid Analgesics Market Share, By Route of Administration, 2022 (E)

Figure 97: MEA Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)

Figure 98: MEA Opioid Analgesics Market Share, By Country, 2022 (E)

Figure 99: MEA Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021

Figure 100: MEA Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 101: MEA Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country

Figure 102: MEA Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class

Figure 103: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication

Figure 104: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

Figure 105: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

Figure 106: Global Opioid Analgesics Market Value Proportion Analysis, By Emerging Countries, 2021

Figure 107: Opioid Analgesics Market, Global Vs. Country Growth Y-o-Y (%) Comparison, 2022-2032

Figure 108: U.S. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 109: U.S. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 110: U.S. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 111: U.S. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 112: Canada Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 113: Canada Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 114: Canada. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 115: Canada. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 116: Brazil. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 117: Brazil. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 118: Brazil. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 119: Brazil. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 120: Mexico. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 121: Mexico. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 122: Mexico. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 123: Mexico. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 124: UK. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 125: UK. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 126: UK. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 127: UK. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 128: Germany. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 129: Germany. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 130: Germany. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 131: Germany. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 132: Italy. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 133: Italy. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 134: Italy. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 135: Italy. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 136: France. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 137: France. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 138: France. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 139: France. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 140: Spain. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 141: Spain. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 142: Spain. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 143: Spain. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 144: Russia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 145: Russia. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 146: Russia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 147: Russia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 148: BENELUX Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 149: BENELUX Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 150: BENELUX Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 151: BENELUX Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 152: China. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 153: China. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 154: China. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 155: China. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 156: Japan. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 157: Japan. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 158: Japan. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 159: Japan. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 160: South Korea. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 161: South Korea. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 162: South Korea. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 163: South Korea. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 164: India. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 165: India. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 166: India. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 167: India. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 168: Thailand. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 169: Thailand. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 170: Thailand. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 171: Thailand. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 172: Indonesia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 173: Indonesia. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 174: Indonesia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 175: Indonesia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 176: Malaysia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 177: Malaysia. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 178: Malaysia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 179: Malaysia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 180: Australia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 181: Australia. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 182: Australia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 183: Australia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 184: New Zealand Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 185: New Zealand Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 186: New Zealand Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 187: New Zealand Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 188: Turkey Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 189: Turkey Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 190: Turkey Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 191: Turkey Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 192: GCC Countries Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 193: GCC Countries Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 194: GCC Countries Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 195: GCC Countries Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 196: South Africa Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 197: South Africa Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032

Figure 198: South Africa Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032

Figure 199: South Africa Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Pain Management Devices Market

Published : February 2022

Healthcare

Pain Monitoring Devices Market

Published : January 2018

Healthcare

Pain Therapeutic Solutions Market

Published : February 2016

Google translate

Opioid Analgesics Market